412. Clinical and Pharmacoeconomic Evaluation of Antifungal Prophylaxis with Continuous Micafungin compared to Posaconazole with Micafungin Bridging in Patients Undergoing Allogeneic Stem Cell Transplantation: A six-year Cohort-Analysis
Session: Poster Abstract Session: Fungal Disease: Management and Outcomes
Thursday, October 4, 2018
Room: S Poster Hall
  • IDWeek2018_PE-Micafungin_2018-09-24_SH.pdf (736.2 kB)
  • Background:

    Patients undergoing allogeneic stem cell transplantation (aSCT) are at high risk of invasive fungal disease (IFD). Optimization of antifungal prophylaxis strategies may further improve patient outcomes and reduce treatment costs.


    We performed a retrospective single-center pharmacoeconomic evaluation comparing patients who received either posaconazole oral solution plus micafungin as intravenous bridging as required (POS-MIC) to patients who received only micafungin (MIC) as antifungal prophylaxis after aSCT at the University Hospital of Cologne. Epidemiological, clinical, and direct treatment cost data extracted from the Cologne Cohort of Neutropenic Patients (CoCoNut) were analyzed. Revised 2008 EORTC/MSG criteria were used for classification of IFD.


    During the observation period from 01/2010 to 12/2015, 313 patients (97 patients in the POS-MIC and 216 patients in the MIC group) fulfilled inclusion criteria. Most patients were male (n= 174; 56%) and median age was 52 years (range: 18 – 75 years). Acute myeloid leukemia was the most common underlying disease (n= 146; 47%). In the POS-MIC and MIC group, median overall length of stay (LOS) was 42 days (IQR: 35 – 52 days) vs. 40 days (IQR: 35 – 49 days; P= 0.296), resulting in median overall direct treatment costs of €42,964 (IQR: 35,040 - €56,348) vs. €43,291 (IQR: €37,281 vs. €51,848; P= 0.993), respectively. In both groups, possible IFD occurred in 6 patients (6%) vs. 16 patients (7%; P= 0.696) and probable/proven IFD occurred in 5 patients (5%) vs. 3 patients (1%; P= 0.051). Overall in-hospital mortality rates in the POS-MIC and MIC group were 10% (n= 10) and 4% (n= 9; P= 0.035). Kaplan-Meier analysis showed improved outcome of patients who received MIC at day 100 (P= 0.037) and at day 365 (P< 0.001) following aSCT. Multivariable cox-regression model demonstrated treatment on ICU as the most important independent covariate for mortality at day 100 (HR: 8.08; P< 0.001) and at day 365 (HR: 4.70; P< 0.001).


    We observed a higher mortality in patients receiving POS-MIC instead of MIC, which was not explained by breakthrough IFDs. The higher drug acquisition costs of micafungin compared to posaconazole oral solution did not translate into higher overall direct treatment costs.

    Sebastian M. Heimann, PhD1, Maria J. G. T. Vehreschild, MD2, Bernd Franke, Database development3, Oliver Cornely, MD, FACP, FIDSA, FAAM3, Axel Hamprecht, MD4, Ellen Piepenbrock, MD5, Christoph Scheid, MD3 and Janne Vehreschild, Prof. Dr. med.6, (1)Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany, (2)University Hospital of Cologne and German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany, (3)University Hospital of Cologne, Cologne, Germany, (4)Institute for Medical Microbiology, Immunology and Hygiene, University Hospital of Cologne, Cologne, Germany, (5)University Hospital Cologne, Cologne, Germany, (6)German Center for Infection Research, Cologne-Bonn, Cologne, Germany


    S. M. Heimann, Astellas: Grant Investigator and Lecture honoraria , Research grant and Speaker honorarium .

    M. J. G. T. Vehreschild, Astellas: Grant Investigator and Speaker's Bureau , Research grant .

    B. Franke, None

    O. Cornely, Astellas: Consultant , Grant Investigator and Lecture honoraria , Consulting fee , Research grant and Speaker honorarium .

    A. Hamprecht, None

    E. Piepenbrock, None

    C. Scheid, None

    J. Vehreschild, Astellas: Grant Investigator and Speaker's Bureau , Research grant and Speaker honorarium .

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.